Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.30 USD
−12.66 M USD
63.05 M USD
19.23 M
About OREXO AB
Sector
CEO
Nikolaj Sørensen
Headquarters
Uppsala
Website
Founded
1994
ISIN
SE0000736415
FIGI
BBG0042VSSM4
Orexo AB engages in the development of pharmaceuticals based on innovative drug delivery technologies. It operates through the following segments: US Pharma, Digital Therapeutics (DTx), and HQ and Pipelines. The US Pharma segment include sales of own pharmaceuticals in the US. The DTx segment comprises digital therapeutic venture. The HQ and Pipeline segment focuses in the out-licensed pharmaceuticals and costs for research and development, business development, global regulatory, and supply chain. The company was founded by Thomas Lundqvist on November 18, 1994 and is headquartered in Uppsala, Sweden.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ORXOF is 1.51 USD — it has increased by 26.47% in the past 24 hours. Watch Orexo AB stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Orexo AB stocks are traded under the ticker ORXOF.
ORXOF reached its all-time high on May 15, 2020 with the price of 7.70 USD, and its all-time low was 1.04 USD and was reached on May 8, 2023. View more price dynamics on ORXOF chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ORXOF stock is 20.93% volatile and has beta coefficient of 0.77. Track Orexo AB stock price on the chart and check out the list of the most volatile stocks — is Orexo AB there?
Today Orexo AB has the market capitalization of 38.33 M, it has decreased by −5.59% over the last week.
Yes, you can track Orexo AB financials in yearly and quarterly reports right on TradingView.
Orexo AB is going to release the next earnings report on Feb 6, 2025. Keep track of upcoming events with our Earnings Calendar.
ORXOF earnings for the last quarter are −0.12 USD per share, whereas the estimation was −0.07 USD resulting in a −61.33% surprise. The estimated earnings for the next quarter are −0.09 USD per share. See more details about Orexo AB earnings.
Orexo AB revenue for the last quarter amounts to 13.38 M USD, despite the estimated figure of 14.51 M USD. In the next quarter, revenue is expected to reach 14.00 M USD.
ORXOF net income for the last quarter is −4.11 M USD, while the quarter before that showed −3.37 M USD of net income which accounts for −21.81% change. Track more Orexo AB financial stats to get the full picture.
No, ORXOF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 27, 2024, the company has 116.00 employees. See our rating of the largest employees — is Orexo AB on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Orexo AB EBITDA is 3.25 M USD, and current EBITDA margin is −7.14%. See more stats in Orexo AB financial statements.
Like other stocks, ORXOF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Orexo AB stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Orexo AB technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Orexo AB stock shows the buy signal. See more of Orexo AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.